Drug Profile
Phentolamine mesylate injectable - Novalar/Septodont
Alternative Names: NV-101; OraVerse; Phentolamine mesilate injectable - Novalar/SeptodontLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novalar Pharmaceuticals
- Developer Novalar Pharmaceuticals; Sanofi; Septodont
- Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Imidazoles; Peripheral vasodilators; Small molecules
- Mechanism of Action Alpha adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaesthesia
Most Recent Events
- 11 Feb 2019 Chemical structure information added
- 11 May 2017 No recent reports on development identified - Registered for Anaesthesia in France and United Kingdom (Submucosal)
- 18 Mar 2011 Septodont acquires injectable phentolamine mesylate from Novalar for North America and unpartnered international markets